LIP
ITOS

Lighthouse Investment Partners’s iTeos Therapeutics ITOS Stock Holding History

Lighthouse Investment Partners’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-24,473
Closed -$334K – 468
2024
Q1 		$334K Buy
+24,473
New +$267K 0.02% 346

Other funds holding ITOS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Lighthouse Investment Partners's ITOS Position: Q2 2024 in Review

Lighthouse Investment Partners sold out of iTeos Therapeutics (ITOS) in Q2 2024, closing a stake of 24,473 shares — an estimated $334K sold.

Lighthouse Investment Partners first reported a position in ITOS in Q1 2024 and held it in 1 quarter. The position peaked at $334K in Q1 2024. 137 funds tracked by Wall St. Rank hold ITOS as of Q2 2024.

  • Lighthouse Investment Partners reported no remaining iTeos Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Lighthouse Investment Partners sold 24,473 iTeos Therapeutics shares in Q2 2024, an estimated $334K.
  • Lighthouse Investment Partners first reported a position in iTeos Therapeutics in Q1 2024 and held it in 1 quarter.
  • Lighthouse Investment Partners's iTeos Therapeutics position peaked at $334K in Q1 2024.
  • 137 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q2 2024.

Based on Lighthouse Investment Partners's 13F filing for Q2 2024, filed 14 Aug 2024.